Source comparison
Dosage Protocols: Clinical Standards vs Research Applications
Clinical trials investigating GHRH-GHRP combinations consistently used 1–2mcg/kg body weight for each peptide, administered subcutaneously. For a 75kg individual, that translates to 75–150mcg of CJC-1295 no DAC and 75–150mcg of Ipamorelin per injection. Resear
This comparison does not assign a generated winner or score.
- Clinical trials investigating GHRH-GHRP combinations consistently used 1–2mcg/kg body weight for each peptide, administered subcutaneously. For a 75kg individual, that translates to 75–150mcg of CJC-1295 no DAC and 75–150mcg of Ipamorelin per injection. Research facilities working with performance or anti-aging protocols typically standardize at 100mcg of each peptide for baseline responders, escalating to 200mcg each for individuals showing suboptimal GH response at the lower dose.
- Timing matters as much as dose. GH secretion naturally peaks during deep slow-wave sleep (stages 3 and 4 of NREM sleep), which typically occurs 60–90 minutes after sleep onset. Administering the peptide stack 30–60 minutes before bed synchronizes the exogenous GH pulse with endogenous nocturnal secretion, amplifying the overnight anabolic window. Morning or midday dosing produces measurable GH elevation but misses the synergistic effect with natural sleep-related GH pulses.
- Frequency protocols vary by application. For metabolic health or anti-aging research, 5 days per week (Monday through Friday, weekends off) prevents receptor downregulation while maintaining elevated weekly GH exposure. For performance-focused research, 7-day protocols are common but require periodic washout periods (2 weeks off every 12 weeks) to reset receptor sensitivity. Split dosing (morning + evening) doubles injection frequency without increasing efficacy. The pituitary's refractory period after a GH pulse means the second dose within 8–12 hours produces diminished response.